Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib

BACKGROUND: In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement characterizes a subgroup of patients who show sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, the prognoses of these patients are heterogeneous. A better understanding of the genomic alte...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jingjing, Zhang, Bin, Zhang, Yu, Xu, Feng, Zhang, Zhenfa, Shao, Lin, Yan, Chunhe, Ulivi, Paola, Denis, Marc G., Christopoulos, Petros, Thomas de Montpréville, Vincent, Bernicker, Eric H., van der Wekken, Anthonie J., Wang, Changli, Yue, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044492/
https://www.ncbi.nlm.nih.gov/pubmed/33889527
http://dx.doi.org/10.21037/tlcr-21-160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044492/
https://www.ncbi.nlm.nih.gov/pubmed/33889527
http://dx.doi.org/10.21037/tlcr-21-160

Ejemplares similares